Cantitate/Preț
Produs

Comparative Genomics and Proteomics in Drug Discovery: Vol 58

Editat de John Parrington, Kevin Coward
en Limba Engleză Paperback – 5 sep 2019
Comparative Genomics and Proteomics in Drug Discovery gives an overview of how emerging genomic and proteomic technologies are making significant contributions to global drug discovery programs, and in particular the key role that comparative genomics and proteomics play within this strategy. Each chapter is written by respected authorities, with hands-on experience, from both academic and pharmaceutical backgrounds.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 48926 lei  6-8 săpt.
  CRC Press – 5 sep 2019 48926 lei  6-8 săpt.
Hardback (1) 178907 lei  6-8 săpt.
  CRC Press – 9 noi 2006 178907 lei  6-8 săpt.

Preț: 48926 lei

Preț vechi: 57560 lei
-15% Nou

Puncte Express: 734

Preț estimativ în valută:
9363 9701$ 7814£

Carte tipărită la comandă

Livrare economică 21 martie-04 aprilie

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9780367389734
ISBN-10: 0367389738
Pagini: 164
Dimensiuni: 156 x 234 x 13 mm
Greutate: 0.45 kg
Ediția:1
Editura: CRC Press
Colecția Taylor & Francis

Public țintă

Professional Practice & Development

Cuprins

 1. Comparative Genomics and Drug Discovery in Trypanosomatids  2. The Practical Implications of Comparative Kinetoplastid Genomics  3. The Relevance of Host Genes in Malaria  4. Nicotinic Acetylcholine Receptors as Drug/Chemical Targets, Contributions from Comparative Genomics, Forward and Reverse Genetics  5. Discovery of Novel Sodium Channel Inhibitors - A Gene Family-Based Approach  6. 'Omics' in Translational Medicine : Are They Lost in Translation?  7. Drug-Target Discovery In Silico : Using the Web to Identify Novel Molecular Targets for Drug Action

Notă biografică

John Parrington and Kevin Coward, Department of Pharmacology, University of Oxford, UK.

Descriere

Comparative Genomics and Proteomics in Drug Discovery gives an overview of how emerging genomic and proteomic technologies are making significant contributions to global drug discovery programs. Each chapter is written by respected authorities, with hands-on experience, from both academic and pharmaceutical backgrounds.